Terminated NA INTERVENTIONAL 2-arm NCT05405764

The CONFUCIUS Oral Protein Supplementation Trial (CONFUCIUS)

CONvalescence of FUntional Outcomes After ICU Stay by Oral Protein Supplementation

Sponsor: ARH van Zanten

Conditions Critical Illness Intensive Care Unit Acquired Weakness

Interventions Control product maltodextrin supplement Porcine protein supplement

Updated 4 times since 2022 Last updated: Sep 23, 2024 Started: Apr 19, 2022 Primary completion: Sep 24, 2024 Completion: Sep 24, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow inclusion rate

Other Critical Illness trials with similar outcome

Browse all Critical Illness trials

A NA clinical study on Critical Illness and Intensive Care Unit Acquired Weakness, this trial is terminated or withdrawn. The trial is conducted by ARH van Zanten and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Oct 2024 — Present [monthly]

Terminated NA

Status: Unknown → Terminated
Sep 2024 — Oct 2024 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Recruiting → Unknown
Jul 2022 — Jul 2024 [monthly]

Recruiting NA

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ARH van Zanten
Intensive Care Research Foundation, Gelderse Vallei Hospital
Rousselot BVBA

Data source: Gelderse Vallei Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ede, Netherlands